At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody Tafasitamab and the immunomodulatory drug Lenalidomide to the standard R-CHOP regimen (hereafter referred to as Tafa-Len+R-CHOP) for the frontline treatment of patients with high-risk diffuse large B-cell lymphoma (DLBCL).

At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the "EHA Research Excellence Award" to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor Vassiliou reviewed the landmark research conducted by his team over the past 15 years regarding the identification of driver genes in acute myeloid leukemia (AML), the evolutionary logic of clonal hematopoiesis (CH), and the development of clinical prediction tools.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Johannes Schetelig from the Technical University Dresden and the German Bone Marrow Donor Center (DKMS) presented a highly anticipated Late-breaking Abstract. This study is a large-scale randomized controlled trial (RCT) designed to compare Anti-T Lymphocyte Globulin (ATLG) and Post-Transplant Cyclophosphamide (PTCy) "head-to-head" for the prophylaxis of Graft-versus-Host Disease (GVHD) in HLA-matched or partially matched unrelated donor hematopoietic cell transplantation (HCT).

At the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Josep Maria Ribera from the Josep Carreras Leukemia Research Institute and the Catalan Institute of Oncology (ICO) was honored with the "EHA Clinical Excellence Award." In his subsequent award lecture, Prof. Ribera systematically reviewed the successful transformation of Acute Lymphoblastic Leukemia (ALL) from a "diagnostic deficiency period" to a "precision immunotherapy period," shared the successful experiences of the Spanish PETEMA group, and outlined a future "chemo-free" treatment blueprint.

At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has become a major challenge for clinicians. This meeting invited Professor Joseph Mikhael from City of Hope, Professor Maria-Victoria Mateos from the University Hospital of Salamanca, and Professor Xavier Leleu from Poitiers University Hospital to conduct an in-depth discussion on "Managing the Burden of MM Treatments."

In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled "From gene profiles to therapy profiles - a quarter century of molecular hematology." Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis of the evolutionary path of hematologic malignancies, represented by Acute Myeloid Leukemia (AML), from morphological classification to molecular precision diagnosis and treatment.

In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment, direct head-to-head data for the second-generation inhibitor gilteritinib versus midostaurin in the context of first-line intensive chemotherapy were previously a blank.